These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1751101)

  • 1. Effects of dialysis factors and route of administration on response of hemodialysis patients to recombinant human erythropoietin.
    Besarab A; Besarab FM; Miller D
    ASAIO Trans; 1991; 37(3):M181-2. PubMed ID: 1751101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients.
    Besarab A; Golper TA
    ASAIO Trans; 1991; 37(3):M395-6. PubMed ID: 1751205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
    Raja R; Bloom E; Goldstein M; Johnson R
    ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
    Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
    Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
    Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
    J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients.
    Trakarnvanich T; Thitiarcharkul S
    J Med Assoc Thai; 2004 Sep; 87(9):1041-7. PubMed ID: 15516004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
    Cotter DJ; Thamer M; Kimmel PL; Sadler JH
    Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased erythropoietin-alpha dose when switching from subcutaneous to intravenous administration: effect of serum albumin.
    Chen HH; Tarng DC; Wu ChJ; Chen YW; Ting JT
    Clin Nephrol; 2008 May; 69(5):347-53. PubMed ID: 18538097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of relative hypoparathyroidism on the responsiveness to recombinant human erythropoietin in hemodialysis patients.
    Hsu SP; Peng YS; Pai MF; Hung KY; Tsai TJ
    Blood Purif; 2003; 21(3):220-4. PubMed ID: 12784047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].
    Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA
    Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
    Faller B; Slingeneyer A; Waller M; Michel C; Grützmacher P; Müller HP; Barany P; Grabensee B; Issad B; Schmitt H
    Clin Nephrol; 1993 Sep; 40(3):168-75. PubMed ID: 8403573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
    Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
    J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route.
    Navarro JF; Teruel JL; Marcén R; Ortuño J
    Scand J Urol Nephrol; 1995 Mar; 29(1):11-4. PubMed ID: 7618043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.